Mayo Clinic develops vaccine vs. breast and pancreatic cancer

• April 23, 2024

The development of a new vaccine that dramatically decreases tumors in model mice that mimic 90% of human cases of breast cancer Y pancreas , even those resistant to treatments, was the result of a study of Mayo Clinic and the University of Georgia (UGA).

According to the coauthor and expert researcher of Mayo Clinic, Dr. Sandra Gendler , the vaccine is unique in its kind, because it enables the immune system to distinguish and eliminate cancer cells based on the different structure of sugar in proteins like the MUC1.

MUC1 is one of the three most important tumor proteins for the development of vaccinations . The protein is present in more than 70% of thecancers that kill like breast, pancreas, ovary and multiple myeloma.

To know a little more about the operation of thevaccine and of the tests that were carried out, in GetQoralHealth we present you a video of the Dr. Gendle r where he explains us about it:

For decades, an attempt has been made to train the immune system to recognize, differentiate and destroy cancer cells instead of normal ones. In this case, the vaccine that they developed does achieve that differentiation and elicits a very strong immune response.

Currently the specialists prove the effectiveness of the vaccine in crops of cancer cells human beings to assess their toxicity. If all goes well, Phase I clinical trials to analyze the safety of thevaccine They could start towards the end of 2013.
 

Follow us onTwitter YFacebook

If you are interested in receiving more information on this topic, do not hesitateregister with us.

Video Medicine: Is the Next Big Step in Cancer Therapy: Personalized Vaccines? (April 2024).